Attitudes of Swiss psychiatrists towards cannabis regulation and medical use in psychiatry: a cross-sectional study.

IF 4.1 Q1 PHARMACOLOGY & PHARMACY
Constantin Strube, Renato Davide Comazzi, Dimitri Löwinger, Reto Auer, Franz Moggi, Philippe Pfeifer
{"title":"Attitudes of Swiss psychiatrists towards cannabis regulation and medical use in psychiatry: a cross-sectional study.","authors":"Constantin Strube, Renato Davide Comazzi, Dimitri Löwinger, Reto Auer, Franz Moggi, Philippe Pfeifer","doi":"10.1186/s42238-023-00210-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Changes in regulation for cannabis for nonmedical use (CNMU) are underway worldwide. Switzerland amended the law in 2021 allowing pilot trials evaluating regulative models for cannabis production and distribution. Simultaneously, cannabis for medical use (CMU) in psychiatry is a growing issue, asked for by patients and being discussed by medical professionals.</p><p><strong>Methods: </strong>From December 2021 to February 2022, we conducted an online survey of psychiatrists in Switzerland. The survey comprised questions on attitudes towards regulative models for CNMU and towards prescribing CMU for mental disorders.</p><p><strong>Results: </strong>We contacted 2010 psychiatrists in Switzerland. A total of 274 (14%) participated in the survey. Sixty-four percent agreed to a regulated legalization of CNMU, and 89% would welcome pilot trials in Switzerland assessing models for regulating CNMU with those from a French-speaking region being more skeptical. Forty-nine percent of psychiatrists agree that CMU might have a therapeutic effect in mental disorders, but 50% agree that there is not enough scientific evidence yet. Participants working in an inpatient setting or in a French-speaking region as well as those with a longer duration of practice were more skeptical on CMU for mental health.</p><p><strong>Conclusions: </strong>Most surveyed Swiss psychiatrists favor the regulation of CNMU and the conduct of pilot trials. Despite little evidence and potential negative consequences, many participating Swiss psychiatrists agreed that cannabis could be efficacious in the treatment of some mental disorders advocating for more research in this topic.</p>","PeriodicalId":101310,"journal":{"name":"Journal of cannabis research","volume":null,"pages":null},"PeriodicalIF":4.1000,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10699035/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cannabis research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42238-023-00210-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Changes in regulation for cannabis for nonmedical use (CNMU) are underway worldwide. Switzerland amended the law in 2021 allowing pilot trials evaluating regulative models for cannabis production and distribution. Simultaneously, cannabis for medical use (CMU) in psychiatry is a growing issue, asked for by patients and being discussed by medical professionals.

Methods: From December 2021 to February 2022, we conducted an online survey of psychiatrists in Switzerland. The survey comprised questions on attitudes towards regulative models for CNMU and towards prescribing CMU for mental disorders.

Results: We contacted 2010 psychiatrists in Switzerland. A total of 274 (14%) participated in the survey. Sixty-four percent agreed to a regulated legalization of CNMU, and 89% would welcome pilot trials in Switzerland assessing models for regulating CNMU with those from a French-speaking region being more skeptical. Forty-nine percent of psychiatrists agree that CMU might have a therapeutic effect in mental disorders, but 50% agree that there is not enough scientific evidence yet. Participants working in an inpatient setting or in a French-speaking region as well as those with a longer duration of practice were more skeptical on CMU for mental health.

Conclusions: Most surveyed Swiss psychiatrists favor the regulation of CNMU and the conduct of pilot trials. Despite little evidence and potential negative consequences, many participating Swiss psychiatrists agreed that cannabis could be efficacious in the treatment of some mental disorders advocating for more research in this topic.

瑞士精神科医生对大麻管制和精神病学医疗使用的态度:一项横断面研究。
背景:在世界范围内,非医疗用途大麻(CNMU)的监管正在发生变化。瑞士于2021年修订了法律,允许进行试点试验,评估大麻生产和分销的监管模式。同时,精神病学的医用大麻(CMU)是一个日益严重的问题,这是病人提出的要求,也是医疗专业人员讨论的问题。方法:从2021年12月到2022年2月,我们对瑞士的精神科医生进行了在线调查。调查的问题包括对CNMU的调节模式和对精神障碍的CMU处方的态度。结果:我们联系了2010名瑞士精神病学家。共有274人(14%)参与了调查。64%的人同意CNMU的监管合法化,89%的人欢迎在瑞士进行试点试验,评估CNMU的监管模式,而来自法语地区的人则持怀疑态度。49%的精神科医生同意CMU可能对精神疾病有治疗作用,但50%的人认为目前还没有足够的科学证据。在住院环境或法语地区工作的参与者,以及那些实习时间较长的参与者,对CMU在心理健康方面的作用持更加怀疑的态度。结论:大多数接受调查的瑞士精神科医生赞成对CNMU进行监管和开展试点试验。尽管几乎没有证据和潜在的负面影响,但许多参与的瑞士精神病学家一致认为,大麻可能有效治疗一些精神障碍,并主张在这一主题上进行更多研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信